A comparative evaluation of the efficacy and safety of clonidine and atomoxetine combined with behavioural interventions in children with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder
- 1Al-Najaf Health Directorate, Najaf Province, Iraq
- 2Department of Clinical Pharmacy, Faculty of Pharmacy, University of Kufa, Najaf, Iraq
Abstract
Objective: To compare the clinical efficacy and safety of atomoxetine versus clonidine, each combined with structured behavioural interventions, in children aged 6–12 years with autism spectrum disorder (ASD) and comorbid attention-deficit/hyperactivity disorder (ADHD).
Methods: A retrospective observational cohort study was conducted at the Imam Al-Hussein Institute for Children with Autism in Najaf, Iraq, between October 2025 and March 2026. Sixty-two children were allocated to two equal groups: atomoxetine plus behavioural intervention (n=31) or clonidine plus behavioural intervention (n=31). Outcomes were measured using DSM‑5 criteria and Conners’ Rating Scales at baseline and three follow‑up intervals (1–3, 3–6, and 6–12 months). Data were analysed using two‑way repeated‑measures ANOVA, Bonferroni post‑hoc tests, and chi‑square tests.
Results: The atomoxetine group showed significantly greater mean symptom improvement than the clonidine group (mean improvement score –13.4 vs. –9.5; p=0.0011), with effects emerging after 3 months and increasing over time. Adverse effects were more frequent in the clonidine group, notably sedation (70.9% vs. 9.6%), irritability (45% vs. 12.9%), and fatigue (61.2% vs. 16.4%). Atomoxetine was associated with mild appetite loss (35%) and gastrointestinal symptoms (29%).
Conclusion: Atomoxetine combined with behavioural intervention demonstrated superior and more sustained clinical improvement and a more favourable safety profile than clonidine in this observational cohort. However, owing to the non‑randomised design and baseline imbalances, these findings should be viewed as hypothesis‑generating. Randomised controlled trials are needed to confirm superiority.
Related
- The Efficacy of Group Cognitive Behavioural Therapy for Reducing Attention-Deficit Hyperactivity Disorder Symptoms and Impairment in Indian University Students: A Randomized Controlled Trial
- Comparative evaluation of HIV testing interventions for men who have sex with men in the Netherlands
- Smoking cessation interventions in adults with attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD).
- Multimodal Machine Learning Approaches to Detect Attention-Deficit/Hyperactivity Disorder (ADHD) Using Physiological and Behavioural Biomarkers: A Systematic Review.
- Co-development, initial evaluation and implementation of a digital health intervention (SmartADHD) for young people (aged 16-30) with attention deficit hyperactivity disorder, including optimisation for sustainable delivery via health and social care settings: protocol for a mixed-methods study.
BibTeX
@article{noor2026comparative,
title = {{A comparative evaluation of the efficacy and safety of clonidine and atomoxetine combined with behavioural interventions in children with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder}},
author = {Murtadha Abd Noor and Dunya Shnain},
journal = {Babcock University Medical Journal},
year = {2026},
month = oct,
doi = {10.38029/babcockuniv.med.j..v9is1.1634},
url = {https://doi.org/10.38029/babcockuniv.med.j..v9is1.1634},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - A comparative evaluation of the efficacy and safety of clonidine and atomoxetine combined with behavioural interventions in children with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder
AU - Murtadha Abd Noor
AU - Dunya Shnain
PY - 2026
DA - 2026/10/01
JO - Babcock University Medical Journal
DO - 10.38029/babcockuniv.med.j..v9is1.1634
UR - https://doi.org/10.38029/babcockuniv.med.j..v9is1.1634
AB - Objective: To compare the clinical efficacy and safety of atomoxetine versus clonidine, each combined with structured behavioural interventions, in children aged 6–12 years with autism spectrum disorder (ASD) and comorbid attention-deficit/hyperactivity disorder (ADHD). Methods: A retrospective observational cohort study was conducted at the Imam Al-Hussein Institute for Children with Autism in Najaf, Iraq, between October 2025 and March 2026. Sixty-two children were allocated to two equal groups: atomoxetine plus behavioural intervention (n=31) or clonidine plus behavioural intervention (n=31). Outcomes were measured using DSM‑5 criteria and Conners’ Rating Scales at baseline and three follow‑up intervals (1–3, 3–6, and 6–12 months). Data were analysed using two‑way repeated‑measures ANOVA, Bonferroni post‑hoc tests, and chi‑square tests. Results: The atomoxetine group showed significantly greater mean symptom improvement than the clonidine group (mean improvement score –13.4 vs. –9.5; p=0.0011), with effects emerging after 3 months and increasing over time. Adverse effects were more frequent in the clonidine group, notably sedation (70.9% vs. 9.6%), irritability (45% vs. 12.9%), and fatigue (61.2% vs. 16.4%). Atomoxetine was associated with mild appetite loss (35%) and gastrointestinal symptoms (29%). Conclusion: Atomoxetine combined with behavioural intervention demonstrated superior and more sustained clinical improvement and a more favourable safety profile than clonidine in this observational cohort. However, owing to the non‑randomised design and baseline imbalances, these findings should be viewed as hypothesis‑generating. Randomised controlled trials are needed to confirm superiority.
SN - 2465-6666
SN - 2756-4657
ER -